Erytec Pharma : Major trigger at end-2020: interim data for phase III trial in pancreatic cancer
>Company contact - Our recent contact with Eric Soyer, CFO of Erytech Pharma, provided an update on the company’s activity in the context of COVID-19. We also discussed last week's announcements concerning the progress of TRYbeCA-1 phase 3 trial.COVID-19: limited impact, which is fairly standard for a biotech - We estimate that for the biotech sector, the COVID-19 impact will show through mainly in the form of delays at the clinical and/or regulatory ...Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.